Why These 15 Stocks Are Skyrocketing in 2025
The market has started to favor smaller companies in 2025, and stocks between $1 billion and $5 billion in market value are attracting renewed interest.
Vir Biotechnology Inc. (VIR)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | OrbiMed Advisors Samuel Isaly | 3,218,617 | $23,624,649 | -10% | 0.48% |
| 2. | Millennium Management Israel Englander | 1,715,083 | $12,588,709 | +56% | 0% |
| 3. | Renaissance Technologies Jim Simons | 1,237,600 | $9,083,984 | +5% | 0.01% |
| 4. | Baker Bros. Advisors Julian Baker And Felix Baker | 1,084,539 | $7,960,516 | 0.08% | |
| 5. | Sio Capital Michael Castor | 1,054,651 | $7,741,138 | 2.17% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.73 | 2,500 | Director | 10,000 | 2023-03-01 | Filing | |
| $24.96 | 2,500 | Director | 7,500 | 2023-01-05 | Filing | |
| $25.25 | 2,500 | Director | 5,000 | 2023-01-04 | Filing | |
| $25.60 | 2,500 | Director | 2,500 | 2023-01-03 | Filing | |
| $43.39 | 12 | Officer | 12 | 2021-11-29 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.81 | 10,964 | Director | 708,295 | 2025-02-18 | Filing | |
| $9.15 | 1,562 | Officer | 28,189 | 2025-02-13 | Filing | |
| $12.52 | 10,960 | Director | 1,312,391 | 2025-01-08 | Filing | |
| $8.22 | 76 | Officer | 56,973 | 2024-12-02 | Filing | |
| $10.11 | 4,397 | Officer | 56,973 | 2024-11-06 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,684,041 | $122,460,861 | 1.07% | |
| 2. | 16,462,717 | $120,836,342 | 0% | |
| 3. | 13,130,635 | $96,378,861 | 0% | |
| 4. | 5,074,731 | $37,248,526 | 0% | |
| 5. | 2,196,601 | $16,127,025 | 0% |
News See All
Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2024 Earnings Call Transcript
Operator: [Call starts abruptly] …Vir's Third Quarter 2024 Financial Results and Business Update Call. As a reminder, this conference call is being recorded.
Vir Biotechnology, Inc. (NASDAQ:VIR) Q2 2024 Earnings Call Transcript
Operator: Hello. Welcome to Vir Biotechnology’s Second Quarter 2024 Financial Results and Business Update Call. As a reminder, this conference call is being recorded.
Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2024 Earnings Call Transcript
Operator: Hello. Welcome to Vir Biotechnology’s First Quarter 2024 Financial Results and Business Update Call. As a reminder, this conference call is being recorded.
Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2023 Earnings Call Transcript
Vir Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.86, expectations were $-1.14. Vir Biotechnology, Inc.
Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2023 Earnings Call Transcript
Operator: Hello, and welcome to Vir Biotechnology's Third Quarter 2023 Financial Results and Business Update Call. As a reminder, this conference call is being recorded.
10 Oversold Healthcare Stocks to Buy
In this article, we will take a look at the 10 healthcare stocks to buy.
Vir Biotechnology, Inc. (NASDAQ:VIR) Q2 2023 Earnings Call Transcript
Operator: Hello. Welcome to Vir Biotechnology Second Quarter 2023 Financial Results and Business Update Call. As a reminder, this conference call is being recorded.
5 Oversold NASDAQ Stocks to Buy
San Francisco, California-based Vir Biotechnology, Inc. (NASDAQ:VIR) is a commercial-stage immunology company focused on the development of therapies to treat and prevent serious infectious diseases.
Billionaire Hedge Funds
